论文部分内容阅读
近日,第二军医大学长海医院风湿免疫科戴生明教授领衔的课题组在类风湿关节炎研究领域获得新的突破,发现大麻素Ⅱ型受体可能成为类风湿关节炎的一个潜在治疗靶点。这一研究结果于2014年1月17日被Rheumatology(Oxford)在线预发表,立即引起国际同行高度关注,并被Nature子刊Nature Review Rheumatology作为研究亮点进行推介。该课题受到国家自然科学基金资助,课题组发现类风湿关节炎患者的滑膜组织和成纤维样滑膜细胞表达大麻素Ⅱ型受体。在炎症环境下,体外培养的类风湿关节炎成纤维样滑膜细胞大麻素型受体的表达水平升高,该受体的选择性激动剂可
Recently, the research group led by Professor Dai Shengming, Department of Rheumatology, Changhai Hospital, Second Military Medical University made a new breakthrough in the field of rheumatoid arthritis and found that cannabinoid type II receptor may become a potential therapeutic target for rheumatoid arthritis. This study, published online by Rheumatology (Oxford) on January 17, 2014, immediately caught the attention of international colleagues and was featured as a research highlight by Nature Review Rheumatology. The subject is funded by the National Natural Science Foundation, the research group found that patients with rheumatoid arthritis synovial tissue and fibroblast-like synoviocytes express cannabinoid type II receptors. In an inflammatory environment, the expression level of the cannabinoid receptor of rheumatoid arthritis fibroblast-like synoviocytes cultured in vitro is increased, and the selective agonist of the receptor may